株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

骨粗鬆症治療薬:世界市場の分析・予測

Osteoporosis: Global Drug Forecast and Market Analysis to 2027

発行 GlobalData 商品コード 661464
出版日 ページ情報 英文 195 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.65円で換算しております。
骨粗鬆症治療薬:世界市場の分析・予測 Osteoporosis: Global Drug Forecast and Market Analysis to 2027
出版日: 2019年03月29日 ページ情報: 英文 195 Pages
概要

2017年における世界の骨粗鬆症治療薬の市場はブランド薬・ジェネリック薬を合わせ計74億ドルと推計されています。

当レポートでは、世界の骨粗鬆症治療薬の市場を調査し、疾患概要・疫学、有病者数、疾患管理の動向、主な製品の概要、アンメットニーズおよび市場機会の分析、パイプラインの動向、主要企業のプロファイル、主要地域・国別の成長推進因子・障壁の分析、市場成長予測などをまとめています。

第1章 目次

第2章 エグゼクティブサマリー

第3章 イントロダクション

第4章 疾患概要

  • 病因・病態生理
  • 分類
  • 症状
  • 予後
  • QoL

第5章 疫学

  • 疾患の背景
  • リスク要因・併存症
  • これまでの推移
  • 予測手法
  • 骨粗鬆症の疫学的予測
    • 総有病者数
    • 有病者数:年齢別
    • 有病者数:年齢別
    • 総有病者数:原発性・続発性別
    • 原発性骨粗鬆症の有病者数:タイプ別
    • グルココルチコイド誘発性骨粗鬆症の総有病者数
    • 診断有病者数
    • 診断有病者数:年齢別
    • 診断有病者数:年齢別
    • 診断有病者数:原発性・続発性別
    • 原発性骨粗鬆症の診断有病者数:タイプ別
    • グルココルチコイド誘発性骨粗鬆症の総有病者数
    • 骨減少症の総有病者数・診断有病者数
  • ディスカッション

第6章 疾患管理

  • 診断
  • 治療
  • 米国
  • EU5カ国
  • 日本

第7章 競合分析

  • 概要
  • ビスリン酸
  • Prolia (デノスマブ)
  • 副甲状腺ホルモン
    • Forteo (テリパラタイド)
    • Tymlos (アバロパラチド)
  • SERM
    • Evista (ラロキシフェン塩酸塩)・ジェネリック薬
    • Viviant (バゼドキシフェン)
    • Duavee (バゼドキシフェン酢酸塩 + 結合型エストロゲン)
  • その他
    • Miacalcin/Fortical (サケカルシトニン)
    • Protelos・ジェネリック薬 (ラネル酸ストロンチウム)
    • エストロゲン/ホルモン補充薬

第8章 市場機会の分析・アンメットニーズ

  • 概要
  • 早期発見・治療
    • アンメットニーズ
  • 服薬コンプライアンス改善
    • アンメットニーズ
    • ギャップ分析
    • 市場機会
  • 長期治療の安全性プロファイルの改善
    • アンメットニーズ
    • ギャップ分析
    • 市場機会
  • 骨形成刺激治療
    • アンメットニーズ
    • ギャップ分析
    • 市場機会

第9章 パイプラインの分析

  • 概要
  • 臨床試験マッピング
  • 臨床開発中の有望薬
    • Evenity (ロモソズマブ)
  • 開発中のその他の薬剤
  • バイオシミラー
    • テリパラタイドバイオシミラー
    • デノスマブバイオシミラー

第10章 現在の企業・将来有望の企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル
    • Amgen
    • Eli Lilly
    • Radius Health
    • UCB

第11章 市場予測

  • 世界市場
    • 予測
    • 成長推進因子・障壁
  • 米国
    • 予測
    • 主要イベント
    • 成長推進因子・障壁
  • EU5カ国
    • 予測
    • 主要イベント
    • 成長推進因子・障壁
  • 日本
    • 予測
    • 主要イベント
    • 成長推進因子・障壁

第12章 付録

図表

List of Tables

  • Table 1: Osteoporosis: Key Metrics in the 7MM
  • Table 2: Etiology of Primary Osteoporosis
  • Table 3: Etiology of Secondary Osteoporosis
  • Table 4: Diagnosis Classification of Osteoporosis
  • Table 5: Symptoms of Osteoporosis
  • Table 6: Risk Factors and Comorbidities for Osteoporosis
  • Table 7: 7MM Total Prevalent Cases of Osteoporosis by Primary Osteoporosis and Secondary Osteoporosis, Both Sexes, Ages ≥30 Years, N, 2017
  • Table 8: 7MM, Total Prevalent Cases of Primary Osteoporosis by Type, Ages ≥30 Years, N, 2017
  • Table 9: 7MM Diagnosed Prevalent Cases of Osteoporosis by Primary Osteoporosis and Secondary Osteoporosis, Both Sexes, Ages ≥30 Years, N, 2017
  • Table 10: 7MM, Diagnosed Prevalent Cases of Primary Osteoporosis by Type, Ages ≥30 Years, N, 2017
  • Table 11: 7MM Total Prevalent Cases and Diagnosed Prevalent Cases of Osteopenia, Both Sexes, Ages ≥30 Years, N, 2017
  • Table 12: Diagnostic Tests for Osteoporosis
  • Table 13: Diagnosis Classification of Osteoporosis
  • Table 14: Treatment Guidelines for Osteoporosis
  • Table 15: Country Profile - US
  • Table 16: Country Profile - 5EU
  • Table 17: Country Profile - Japan
  • Table 18: Marketed Products for Osteoporosis
  • Table 19: Product Profile - Bisphosphates
  • Table 20: Summary of the Bisphosphates Currently Used for the Treatment of Osteoporosis
  • Table 21: SWOT Analysis - Bisphosphates, 2017
  • Table 22: Product Profile - Prolia
  • Table 23: Efficacy Results from Phase III Study of Prolia for the Treatment of Postmenopausal Osteoporosis
  • Table 24: Efficacy Results from Phase III Study of Prolia as a Treatment to Increase Bone Mass in Men with Osteoporosis
  • Table 25: Adverse Events Reported in ≥2% of Patient Population in Phase III Trial for Prolia in Postmenopausal Osteoporosis
  • Table 26: SWOT Analysis - Prolia, 2017
  • Table 27: Product Profile - Forteo
  • Table 28: Efficacy Results from the Phase III Study of Forteo for the treatment of Postmenopausal Osteoporosis
  • Table 29: Efficacy Results from Phase III Study of Forteo for the Treatment of Osteoporosis in Men
  • Table 30: Efficacy Results from Phase III Study of Forteo for the Treatment of Glucocorticoid-Induced Osteoporosis
  • Table 31: Adverse Events Reported in ≥2% of Patients Treated with Forteo from Two Pivotal Phase III Trials
  • Table 32: Adverse Events Reported in ≥2% of Patients Treated with Forteo from Two Pivotal Phase III Trials
  • Table 33: SWOT Analysis - Forteo, 2017
  • Table 34: Product Profile - Tymlos
  • Table 35: Efficacy Results after 18 months of Tymlos Therapy in Phase III Clinical trial, ACTIVE
  • Table 36: Adverse Events Reported in ≥5% of Patients in ACTIVE Clinical Trial
  • Table 37: SWOT Analysis - Tymlos, 2017
  • Table 38: Product Profile - Evista and Generics
  • Table 39: Raloxifene Hydrochloride Generics Marketed in the 7MM
  • Table 40: Adverse Reactions Reported in Clinical Trials Assessing Evista for the Prevention of Osteoporosis
  • Table 41: Adverse Reactions Reported in Clinical Trials Assessing Evista for the Prevention of Osteoporosis
  • Table 42: SWOT Analysis - Evista, 2017
  • Table 43: Product Profile - Viviant
  • Table 44: SWOT Analysis - Vivant, 2017
  • Table 45: Product Profile - Duavee
  • Table 46: Summary of the SMART Program Investigating Duavee for the Prevention of Postmenopausal Osteoporosis
  • Table 47: Adverse Reactions Reported in ≥5% of Patients in SMART Clinical Trials
  • Table 48: SWOT Analysis - Duavee, 2017
  • Table 49: Product Profile - Evenity
  • Table 50: Efficacy Results from Phase III FRAME Study of Evenity vs. Placebo for the Treatment of Osteoporosis
  • Table 51: Efficacy Results from Phase III ARCH Study of Evenity vs. Alendronate for the Treatment of Osteoporosis
  • Table 52: Safety Results from Phase III FRAME Study of Evenity vs. Placebo for the Treatment of Osteoporosis
  • Table 53: Safety Results from Phase III ARCH Study of Evenity vs. Alendronate for the Treatment of Osteoporosis
  • Table 54: SWOT Analysis - Evenity, 2017
  • Table 55: Early-Stage Drugs in Clinical Development for Osteoporosis in the 7MM, 2018
  • Table 56: Teriparatide Biosimilars in Development, 2018
  • Table 57: Key Companies in the Osteoporosis Market in the 7MM, 2018
  • Table 58: Amgen's Osteoporosis Portfolio Assessment, 2018
  • Table 59: Eli Lilly's Osteoporosis Assessment, 2018
  • Table 60: Radius Health's Osteoporosis Assessment, 2018
  • Table 61: UCB's Osteoporosis Assessment, 2018
  • Table 62: Osteoporosis Market - Global Drivers and Barriers, 2017-2027
  • Table 63: Key Events Impacting Sales for Osteoporosis in the US, 2017-2027
  • Table 64: Osteoporosis Market - Drivers and Barriers in the US, 2017-2027
  • Table 65: Key Events Impacting Sales for Osteoporosis in the 5EU, 2017-2027
  • Table 66: Osteoporosis Market - Drivers and Barriers in the 5EU, 2017-2027
  • Table 67: Key Events Impacting Sales for Osteoporosis in Japan, 2017-2027
  • Table 68: Osteoporosis Market - Drivers and Barriers in Japan, 2017-2027
  • Table 69: Key Historical and Projected Launch Dates for Osteoporosis
  • Table 70: Key Historical and Projected Patent Expiry Dates for Osteoporosis
  • Table 71: Annual Cost of Oral Bisphosphates
  • Table 72: Annual Cost of IV Bisphosphates
  • Table 73: Annual Cost of Prolia (Denosumab)
  • Table 74: Annual Cost of Evista (Raloxifene)
  • Table 75: Annual Cost of Viviant (Bazedoxifene)
  • Table 76: Annual Cost of Duavee (Bazedoxifene + Conjugated Estrogen)
  • Table 77: Annual Cost of Oral Bisphosphates
  • Table 78: Annual Cost of Forteo (Teriparatide)
  • Table 79: Annual Cost of Tymlos (Abaloparatide)
  • Table 80: Predicted Annual Cost of Evenity (Romosozumab)
  • Table 81: High-Prescribing Physicians (Non-KOLs), Surveyed by Country, 2018

List of Figures

  • Figure 1: 7MM Sales Forecast for Osteoporosis, by Country, 2017 and 2027
  • Figure 2: Global Sales of Branded Osteoporosis Products, by Company, 2017-2027
  • Figure 3: Unmet Needs for the Treatment of Osteoporosis, 2017
  • Figure 4: Competitive Assessment of Late-Stage Pipeline Agents in Osteoporosis, 2017-2027
  • Figure 5: Global (7MM) Sales Forecast by Drug Class for Osteoporosis, 2017-2027
  • Figure 6: Etiology of Osteoporosis
  • Figure 7: 7MM, Age-Standardized Total Prevalence of Osteoporosis, Men and Women, Ages ≥30 Years, 2017
  • Figure 8: 7MM, Age-Standardized Diagnosed Prevalence of Osteoporosis, Men and Women, Ages ≥30 Years, 2017
  • Figure 9: 7MM, Sources Used and Not Used to Forecast Total Prevalent Cases of Osteoporosis
  • Figure 10: 7MM, Sources Used to Forecast Total Prevalent Cases and Diagnosed Prevalent Cases of Primary and Secondary Osteoprosis
  • Figure 11: 7MM, Sources Used to Forecast Total Prevalent Cases of Osteopenia
  • Figure 12: 7MM, Sources Used to Forecast Diagnosed Prevalent Cases of Osteoporosis
  • Figure 13: 7MM, Sources Used to Forecast Diagnosed Prevalent Cases of Osteopenia
  • Figure 14: 7MM, Total Prevalent Cases of Osteoporosis, Both Sexes, Ages ≥30 Years, N, 2017
  • Figure 15: 7MM, Age-Specific Total Prevalent Cases of Osteoporosis, Both Sexes, Ages ≥30 Years, N, 2017
  • Figure 16: 7MM, Sex-Specific Total Prevalent Cases of Osteoporosis, Both Sexes, Ages ≥30 Years, N, 2017
  • Figure 17: 7MM, Total Prevalent Cases of Osteoporosis Secondary to Glucocorticoid Use, Both Sexes, Ages ≥30 Years, N, 2017
  • Figure 18: 7MM, Diagnosed Prevalent Cases of Osteoporosis, Both Sexes, Ages ≥30 Years, N, 2017
  • Figure 19: 7MM, Age-Specific Diagnosed Prevalent Cases of Osteoporosis, Both Sexes, Ages ≥30 Years, N, 2017
  • Figure 20: 7MM, Sex-Specific Diagnosed Prevalent Cases of Osteoporosis, Both Sexes, Ages ≥30 Years, N, 2017
  • Figure 21: 7MM, Diagnosed Prevalent Cases of Osteoporosis Secondary to Glucocorticoid Use, Both Sexes, Ages ≥30 Years, N, 2017
  • Figure 22: Osteoporosis Treatment Algorithm
  • Figure 23: Level of Use versus Line of Therapy for Currently Marketed Therapies for Osteoporosis
  • Figure 24: Unmet Needs for the Treatment of Osteoporosis, 2017
  • Figure 25: Overview of the Development Pipeline in Osteoporosis, March 2019
  • Figure 26: Osteoporosis - Key Phase IIB-III Clinical Trials, 2017
  • Figure 27: Competitive Assessment of Late-Stage Pipeline Agents in Osteoporosis, 2017-2027
  • Figure 28: Clinical and Commercial Positioning - Evenity, 2017
  • Figure 29: Global Sales of Branded Osteoporosis Products by Company, 2017-2027
  • Figure 30: Company Portfolio Gap Analysis in Osteoporosis, 2017-2027
  • Figure 31: Global (7MM) Sales Forecast by Country for Osteoporosis in 2017 and 2027
  • Figure 32: Global (7MM) Sales Forecast by Drug Class for Osteoporosis in 2017 and 2027
  • Figure 33: Global (7MM) Sales Forecast by Drug Class for Osteoporosis, 2017-2027
  • Figure 34: Global (7MM) Sales Forecast by Osteoporosis Patient Segment, 2017-2027
  • Figure 35: US Sales Forecast by Drug Class for Osteoporosis in 2017 and 2027
  • Figure 36: 5EU Sales Forecast by Country for Osteoporosis in 2017 and 2027
  • Figure 37: 5EU Sales Forecast by Drug Class for Osteoporosis in 2017 and 2027
  • Figure 38: Japan Sales Forecast by Drug Class for Osteoporosis in 2017 and 2027
目次
Product Code: GDHC176PIDR

Osteoporosis is a disease in which the density and quality of bone are reduced over time. In a natural process known as remodeling, some of the bone cells dissolve (resorption) and new bone cells grow back (formation). For people with osteoporosis, bone loss outpaces the growth of new bone. Consequently, bones become more porous and fragile, leading to weakness of the skeleton and an increased risk of hip, spine, and wrist fractures. Osteoporosis is often referred to as a "silent" disease, because the loss of bone occurs progressively and often there are no symptoms until the first fracture occurs.

Despite being a market currently monopolized by generics, osteoporosis is expected to undergo substantial change between 2017 and 2027. Clear changes are already being seen with the recent launch of Radius Health's Tymlos (abaloparatide) in the US in 2017. Anabolic agents are likely to further revolutionize the market with the arrival of a novel sclerostin inhibitor, Evenity (romosozumab), and teriparatide biosimilars. This diversification of the anabolic offering will increase competition in this space, driving down high price tags and potentially bolstering the use of these therapies up the treatment paradigm. The launch of Evenity will keep Amgen a key player in the osteoporosis market as they lose patent protection of current market leading therapy, Prolia (denosumab). The arrival of new anabolic agents and the loss of patent protection for key branded therapies will shape the osteoporosis market over the forecast period. However, poor diagnosis rates, badly perceived drug side effects, and low compliance rates will continue to prove major barriers to growth over the next 10 years.

Key Questions Answered

What are the key osteoporosis treatments in 2017?

When will the late stage pipeline products launch, and how will it affect drug sales and the overall osteoporosis market in the 7MM?

Which unmet needs will remain unaddressed in the forecast period and what opportunities remain for pharmaceutical companies?

Scope

  • Overview of osteoporosis, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized osteoporosis therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in four patient segments (postmenopausal, male, glucocorticoid-induced and osteopenia) forecast from 2017 to 2027.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the osteoporosis therapeutics market
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for osteoporosis therapy. The most promising candidates in Phase III development are profiled.
  • Analysis of the current and future market competition in the global osteoporosis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global osteoporosis therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global osteoporosis therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Osteoporosis: Executive Summary

  • 2.1 Sales for Osteoporosis by Region, 2017-2027
  • 2.2 Anabolic Therapy Will Be the Product of Choice for Future Players
  • 2.3 Low Diagnosis Rates and Compliance Leave Key Unmet Needs in the Osteoporosis Market
  • 2.4 Current Market Leader Prolia Will Make Way for New Anabolic Therapies
  • 2.5 Biosimilars Will Dominate the Market in 2027
  • 2.6 What Do Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology
  • 4.2 Classification
  • 4.3 Symptoms
  • 4.4 Prognosis
  • 4.5 Quality of Life

5 Epidemiology

  • 5.1 Disease Background
  • 5.2 Risk Factors and Comorbidities
  • 5.3 Global and Historical Trends
  • 5.4 Forecast Methodology
    • 5.4.1 Sources
    • 5.4.2 Forecast Assumptions
  • 5.5 Epidemiological Forecast for Osteoporosis (2017-2027)
    • 5.5.1 Total Prevalent Cases of Osteoporosis
    • 5.5.2 Age-Specific Total Prevalent Cases of Osteoporosis
    • 5.5.3 Sex-Specific Total Prevalent Cases of Osteoporosis
    • 5.5.4 Total Prevalent Cases of Osteoporosis by Primary and Secondary Osteoporosis
    • 5.5.5 Total Prevalent Cases of Primary Osteoporosis by Type
    • 5.5.6 Total Prevalent Cases of Osteoporosis Secondary to Glucocorticoid Use
    • 5.5.7 Diagnosed Prevalent Cases of Osteoporosis
    • 5.5.8 Age-Specific Diagnosed Prevalent Cases of Osteoporosis
    • 5.5.9 Sex-Specific Diagnosed Prevalent Cases of Osteoporosis
    • 5.5.10 Diagnosed Prevalent Cases of Osteoporosis by Primary and Secondary Osteoporosis
    • 5.5.11 Diagnosed Prevalent Cases of Primary Osteoporosis by Type
    • 5.5.12 Diagnosed Prevalent Cases of Osteoporosis Secondary to Glucocorticoid Use
    • 5.5.13 Total Prevalent Cases and Diagnosed Prevalent Cases of Osteopenia
  • 5.6 Discussion
    • 5.6.1 Epidemiological Forecast Insight
    • 5.6.2 Limitations of the Analysis
    • 5.6.3 Strengths of the Analysis

6 Disease Management

  • 6.1 Diagnosis Overview
  • 6.2 Treatment Overview
    • 6.2.1 Treatment Guidelines
    • 6.2.2 Disease Management
  • 6.3 US
  • 6.4 5EU
  • 6.5 Japan

7 Competitive Assessment

  • 7.1 Overview
  • 7.2 Bisphosphates
    • 7.2.1 Overview
    • 7.2.2 Efficacy
    • 7.2.3 Safety
    • 7.2.4 SWOT Analysis
    • 7.2.5 Forecast
  • 7.3 Prolia (Denosumab)
    • 7.3.1 Overview
    • 7.3.2 Efficacy
    • 7.3.3 Safety
    • 7.3.4 SWOT Analysis
    • 7.3.5 Forecast
  • 7.4 Parathyroid Hormones
    • 7.4.1 Forteo (Teriparatide)
    • 7.4.2 Tymlos (Abaloparatide)
  • 7.5 SERMs
    • 7.5.1 Evista (Raloxifene Hydrochloride) and Generics
    • 7.5.2 Viviant (Bazedoxifene)
    • 7.5.3 Duavee (Bazedoxifene Acetate + Conjugated Estrogens)
  • 7.6 Other Therapies for the Treatment of Osteoporosis
    • 7.6.1 Miacalcin/Fortical (Salmon Calcitonin)
    • 7.6.2 Protelos and Generics (Strontium Ranelate)
    • 7.6.3 Estrogen/Hormone Replacement Therapies

8 Opportunity Analysis and Unmet Needs

  • 8.1 Overview
  • 8.2 Earlier Disease Detection and Treatment
    • 8.2.1 Unmet Need
  • 8.3 Improved Compliance
    • 8.3.1 Unmet Need
    • 8.3.2 Gap Analysis
    • 8.3.3 Opportunity
  • 8.4 Improved Safety Profile of Long-Term Treatments
    • 8.4.1 Unmet Need
    • 8.4.2 Gap Analysis
    • 8.4.3 Opportunity
  • 8.5 Therapies that Stimulate Bone Formation
    • 8.5.1 Unmet Need
    • 8.5.2 Gap Analysis
    • 8.5.3 Opportunity

9 Pipeline Assessment

  • 9.1 Overview
  • 9.2 Promising Drugs in Clinical Development
    • 9.2.1 Evenity (Romosozumab)
  • 9.3 Other Drugs in Development
  • 9.4 Biosimilars
    • 9.4.1 Teriparatide Biosimilars
    • 9.4.2 Denosumab Biosimilars

10 Current and Future Players

  • 10.1 Overview
  • 10.2 Trends in Corporate Strategy
  • 10.3 Company Profiles
    • 10.3.1 Amgen
    • 10.3.2 Eli Lilly
    • 10.3.3 Radius Health
    • 10.3.4 UCB

11 Market Outlook

  • 11.1 Global Markets
    • 11.1.1 Forecast
    • 11.1.2 Drivers and Barriers - Global Issues
  • 11.2 US
    • 11.2.1 Forecast
    • 11.2.2 Key Events
    • 11.2.3 Drivers and Barriers
  • 11.3 5EU
    • 11.3.1 Forecast
    • 11.3.2 Key Events
    • 11.3.3 Drivers and Barriers
  • 11.4 Japan
    • 11.4.1 Forecast
    • 11.4.2 Key Events
    • 11.4.3 Drivers and Barriers
  • 12 Appendix
  • 12.1 Bibliography
  • 12.2 Abbreviations
  • 12.3 Methodology
    • 12.3.1 Forecasting Methodology
    • 12.3.2 Diagnosed Patients
    • 12.3.3 Percent Drug-Treated Patients
    • 12.3.4 Drugs Included in Each Therapeutic Class
    • 12.3.5 Launch and Patent Expiry Dates
    • 12.3.6 General Pricing Assumptions
    • 12.3.7 Individual Drug Assumptions
    • 12.3.8 Generic Erosion
    • 12.3.9 Pricing of Pipeline Agents
  • 12.4 Primary Research
    • 12.4.1 KOLs
    • 12.4.2 Primary Research - Prescriber Survey
  • 12.5 About the Authors
    • 12.5.1 Analyst
    • 12.5.2 Therapy Area Director
    • 12.5.3 Epidemiologist
    • 12.5.4 Managing Epidemiologist
    • 12.5.5 Global Director of Therapy Analysis and Epidemiology
    • 12.5.6 Global Head and EVP of Healthcare Operations and Strategy
  • 12.6 About GlobalData
  • 12.7 Contact Us
  • 12.8 Disclaimer